Drug Master File: Difference between revisions
UrielAcosta (talk | contribs) Per WP:Copyright violations, removed material copied from https://www.americanpharmaceuticalreview.com/Featured-Articles/594397-The-Lifecycle-from-Drug-Development-Through-Approval-Processes/ Tags: Visual edit Mobile edit Mobile web edit |
Phil herbs (talk | contribs) Adding local short description: "Document in the pharmaceutical industry", overriding Wikidata description "document in the pharmaceutical industry" |
||
| (5 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Document in the pharmaceutical industry}} |
|||
{{Multiple issues |
{{Multiple issues| |
||
|expert = May 2009 |
|||
{{expert needed|Pharmacology|date = May 2009}} |
|||
|orphan = February 2009 |
|||
{{confusing|date = May 2009}} |
|||
{{more footnotes|date = May 2009}} |
|||
}} |
|||
'''Drug Master File''' or '''DMF''' is a document prepared by a [[pharmaceutical]] manufacturer and submitted solely at its discretion to the appropriate regulatory authority in the intended drug market. There is no regulatory requirement to file a DMF. However, the document provides the regulatory authority with confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. Typically, a DMF is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its [[intellectual property]] from its partner while complying with regulatory requirements for disclosure of processing details. |
'''Drug Master File''' or '''DMF''' is a document prepared by a [[pharmaceutical]] manufacturer and submitted solely at its discretion to the appropriate regulatory authority in the intended drug market. There is no regulatory requirement to file a DMF. However, the document provides the regulatory authority with confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. Typically, a DMF is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its [[intellectual property]] from its partner while complying with regulatory requirements for disclosure of processing details. |
||
| Line 12: | Line 12: | ||
== DMFs in the United States == |
== DMFs in the United States == |
||
In the United States, DMFs are submitted to the [[Food and Drug Administration]] (FDA). The Main Objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product for obtaining an [[Investigational New Drug]] Application (IND), a [[New Drug Application]] (NDA),As an [[Abbreviated New Drug Application]] (ANDA), another DMF, or an Export Application. |
In the United States, DMFs are submitted to the [[Food and Drug Administration]] (FDA). The Main Objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product for obtaining an [[Investigational New Drug]] Application (IND), a [[New Drug Application]] (NDA),As an [[Abbreviated New Drug Application]] (ANDA), another DMF, or an Export Application. |
||
In United States there are 5 types of Drug Master file:<ref name="FDAguideDMF">{{cite web|url=http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122886.htm|title=Guideline for Drug Master Files|publisher=US Food and Drug Administration|accessdate=2009-09-19}}</ref> |
In United States there are 5 types of Drug Master file:<ref name="FDAguideDMF">{{cite web|url=http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122886.htm|title=Guideline for Drug Master Files|publisher=US Food and Drug Administration|accessdate=2009-09-19}}</ref> |
||
| Line 37: | Line 37: | ||
* [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/UCM2007046#download] |
* [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/UCM2007046#download] |
||
* [http://www.usactives.com/z1/index.html DMF search engine] |
* [http://www.usactives.com/z1/index.html DMF search engine] |
||
* [http://www.emea.europa.eu/pdfs/human/qwp/013402.pdf Draft Note for Guidance on the EDMF procedure] |
* [http://www.emea.europa.eu/pdfs/human/qwp/013402.pdf Draft Note for Guidance on the EDMF procedure]{{Dead link|date=February 2024 |bot=InternetArchiveBot |fix-attempted=yes }} |
||
[[Category:Pharmaceutical industry]] |
[[Category:Pharmaceutical industry]] |
||
[[de:Drug Master File]] |
|||
[[fr:Drug Master File]] |
|||
[[ja:ドラッグマスターファイル]] |
|||
Latest revision as of 17:55, 28 February 2024
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Drug Master File or DMF is a document prepared by a pharmaceutical manufacturer and submitted solely at its discretion to the appropriate regulatory authority in the intended drug market. There is no regulatory requirement to file a DMF. However, the document provides the regulatory authority with confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. Typically, a DMF is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its intellectual property from its partner while complying with regulatory requirements for disclosure of processing details.
Description
[edit]Drug Master File (DMF) is a document containing complete information on an Active Pharmaceutical Ingredient (API) or finished drug dosage form. It is known as European Drug Master File (EDMF) or Active Substance Master File (ASMF) and US-Drug Master file (US-DMF) in Europe and United States respectively.
DMFs in the United States
[edit]In the United States, DMFs are submitted to the Food and Drug Administration (FDA). The Main Objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product for obtaining an Investigational New Drug Application (IND), a New Drug Application (NDA),As an Abbreviated New Drug Application (ANDA), another DMF, or an Export Application.
In United States there are 5 types of Drug Master file:[1]
- Type I Manufacturing Site, Facilities, Operating Procedures and Personnel
- Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product
- Type III Packaging Material
- Type IV Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation
- Type V FDA Accepted Reference Information
DMFs in Europe
[edit]The content and the format for drug master file used in United States differs from that used in European Countries to obtain market authorization (MA). The Main Objective of the EDMF is to support regulatory requirements of a medicinal product to prove its quality, safety and efficacy. This helps to obtain a Marketing Authorisation grant.
References
[edit]- ^ "Guideline for Drug Master Files". US Food and Drug Administration. Retrieved 2009-09-19.